Model-Informed Drug Discovery and Development (MID3): Current Landscape and Foundational Principles of Model-Informed T-Cell Engager Development

In this session, Alina Volkova, PhD (Senior Scientist, M&S Decisions) has walked through the essential building blocks of modern bispecific antibody mechanistic models and show how these components are implemented in published case studies and leveraged to support First-in-Human (FIH) dose selection.